Florida lawmakers look to cap biotech investment

Over the past two years, Florida's Innovation Incentive program has pumped all of its money--hundreds of millions of dollars--to persuade a group of prestigious research centers to set up operations in the state. Supporters say that it is one of the most successful economic incentive programs in biotech (and made FierceBiotech's Top 5 biotech economic development list two years running).

But some lawmakers say the state shouldn't be putting all its investment eggs in one biotech basket. A new bill would limit any one industry to half of the funds available and give the state a share of any royalties from commercialization efforts. Palm Beach officials, though, say that a move like that would limit its efforts to attract more biomedical research to the area.

''We are concerned that decreased funding certainly would take away from the momentum that the state has developed in attracting the bioscience industry,'' Kelly Smallridge, president of the Business Development Board of Palm Beach County, told the Palm Beach Post. "There are still a number of sizable institutions considering our location.

- read the article from the Palm Beach Post

Related Articles:
Florida--Top Five Regions Targeting Biotech Companies, 2008. Report
Max Planck Society eyes Florida research center. Report
Florida moves up the charts in tech spin-offs. Report
Florida gets an honorable mention, with a warning. Report
Can Florida woo biotechs? Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.